[123I-IMP clearance of the lung with diffuse lung disease].
N-isopropyl-I-123-p-iodoamphetamine (123I-IMP) is taken up by the capillary endothelial cells during the first pulmonary pass and is released from the lung. To evaluate the effect of the 123I-IMP retention on diffuse lung disease, we studied prolonged 123I-IMP clearance from lung in 5 non-smoking control volunteers and 15 patients with various diffuse lung diseases. The time-activity curve for 60 min after the injection of 111 MBq of 123I-IMP was described as follows: C(t) = A1e-k1t + A2e-k1t (A1, A2: intercepts; K1, K2: slopes of the exponential components). 123I-IMP clearance was delayed in the patient group and K2 was significantly lower. There was a significant correlation between K2 and Ga-computer activity index on the 67Ga scintigraphy in the patient group. K2 was also correlated with %Dlco on the pulmonary function test. Our study suggests that the delayed clearance and retention of 123I-IMP in the diseased lung are influenced by the pathological activity in the lung lesion.
Takahashi
T
T
Department of Radiology, Iwate Medical University.
Kato
K
K
Yanagisawa
T
T
Maiya
N
N
Tamura
M
M
D000368:Aged; D000542:Alveolitis, Extrinsic Allergic / Q000000981:diagnostic imaging / Q000473:pathology; D000662:Amphetamines / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D020367:Iofetamine; D008168:Lung / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D008171:Lung Diseases / Q000000981:diagnostic imaging* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D011009:Pneumoconiosis / Q000000981:diagnostic imaging / Q000473:pathology; D011658:Pulmonary Fibrosis / Q000000981:diagnostic imaging / Q000473:pathology; D011877:Radionuclide Imaging
D000662:Amphetamines; D020367:Iofetamine